Quick Facts

• Primary Use: Treatment of HIV-1 infection.
• Patient Group: Adults and pediatric patients weighing at least 35 kg.
• Treatment Status: Used in patients with no prior antiretroviral history or to replace a current regimen in those who are virologically suppressed.

---

Delstrigo is an established therapeutic option indicated for the management of Human Immunodeficiency Virus type 1 (HIV-1) infection. It is utilized as a complete, single-tablet regimen for adults and for pediatric patients who weigh at least 35 kg.

This medication is typically initiated for individuals who have not received prior antiretroviral treatment. It may also serve to replace an existing stable antiretroviral regimen in patients who have achieved viral suppression and meet specific criteria outlined by a healthcare provider. The goal of this treatment is to help lower the amount of HIV-1 in the blood (viral load) and may support an increase in the count of CD4+ T-cells, which contributes to overall immune function.

Reducing the viral load is an important step in managing the condition and may reduce the risk of associated complications. Delstrigo does not provide a definitive cure for HIV-1 infection.

The eligibility for using Delstrigo is defined by patient status, age, organ function, and current co-medications, as strictly documented in official regulatory labeling.

Populations for Whom Use is Contraindicated

Use of Delstrigo is contraindicated (absolutely prohibited) in individuals who have a known history of hypersensitivity to lamivudine, one of the medicine’s active components. It is also contraindicated when co-administered with drugs that are strong CYP3A enzyme inducers (such as rifampin, carbamazepine, or St. John’s Wort), as this interaction significantly decreases the concentration of doravirine, risking treatment failure.

Age and Weight Requirements

Delstrigo is approved for use in adults with HIV-1 infection. For pediatric patients, eligibility is restricted to those 12 years of age and older who weigh at least 35 kg. Safety and efficacy are not established in children below these defined age and weight thresholds. Limited clinical data are available regarding use in patients aged 65 years and over.

Condition-Based Restrictions

The medicine is a fixed-dose combination, and its components cannot be adjusted. Consequently, Delstrigo is not recommended for patients with severe renal impairment, defined as estimated Creatinine Clearance (CrCl) less than 50 mL/min. Use is also not recommended in patients with severe hepatic impairment (Child-Pugh Class C). Patients co-infected with Hepatitis B Virus (HBV) require close monitoring if the medicine is discontinued due to the risk of severe exacerbation of Hepatitis B.

Pregnancy and Lactation Status

Breastfeeding is not recommended for women taking Delstrigo due to the risk of HIV-1 transmission and the presence of drug components in breast milk. The medicine's effect on an unborn baby is not known; a dedicated Antiretroviral Pregnancy Registry exists for monitoring outcomes.

Interactions with other medicines and products

Co-administration of Delstrigo with certain medicinal products is classified as contraindicated due to a pharmacokinetic interaction. This constraint applies to strong Cytochrome P450 (CYP)3A enzyme inducers, which significantly decrease the plasma concentration of the Doravirine component. Prohibited combinations include anticonvulsants such as Carbamazepine and Phenytoin, the antimycobacterial Rifampin, and the herbal product St. John’s wort (Hypericum perforatum). Delstrigo is also contraindicated with other medicines containing its active ingredients.

Interaction Entity	Regulatory Constraint or Requirement
CYP3A Moderate Inducers	The co-administration with Rifabutin requires a timing-based dose adjustment: an additional Doravirine 100 mg tablet must be taken approximately 12 hours after the daily Delstrigo dose.
Renal Function / Transporters	Concurrent or recent use of nephrotoxic agents, such as high-dose Nonsteroidal Anti-inflammatory Drugs (NSAIDs), should be avoided. These agents may increase the plasma concentration of the Lamivudine and Tenofovir components by competing for active renal tubular secretion.
Non-Drug Substances	Sorbitol-containing medicines should be avoided due to a resulting dose-dependent reduction in Lamivudine exposure.

The fixed-dose combination is officially not recommended for use in patients with estimated creatinine clearance (CrCl) less than 50 mL/min, as the formulation prevents the necessary dose adjustment for the Lamivudine and Tenofovir components.

Delstrigo is a fixed-dose combination that exerts its effect by targeting the Reverse Transcriptase (RT) enzyme of the Human Immunodeficiency Virus type 1 (HIV-1) through three complementary mechanisms. This multitargeted approach disrupts the viral life cycle at the crucial step of converting viral RNA into DNA, which results in the inhibition of viral replication.

Doravirine acts via Non-Nucleoside Reverse Transcriptase Allosteric Inhibition, binding to a specific site on the RT enzyme to alter its structure. This structural change modifies the enzyme's function, which results in the suppression of viral proliferation.

The active metabolites of lamivudine and tenofovir drive Nucleos(t)ide Analogue Chain Termination. These compounds mimic natural DNA building blocks and are competitively incorporated into the nascent viral DNA strand. Their incorporation causes immediate chain termination, which triggers the premature cessation of viral DNA synthesis.

The co-formulation delivers two distinct inhibitor classes (NNRTI and NRTI/NtRTI) that concurrently bind to the same viral target through two different binding mechanisms. This coordinated action influences patterns of drug resistance development and sustains the inhibition of viral replication across the system.

How to Use Delstrigo

Delstrigo is administered as a Fixed-Dose Combination (FDC) Oral Tablet that must be swallowed whole to deliver 100 mg Doravirine, 300 mg Lamivudine, and 300 mg Tenofovir Disoproxil Fumarate. The general principle for its use is a long-term, once-daily regimen.

This medicine is taken by swallowing one tablet orally, once every 24 hours, and it can be taken with or without food. The formulation's components are fixed and cannot be separated for individual dosing adjustments.

Official Administration Guidelines

Administration Aspect	Official Instruction
Standard Dosing	One tablet daily (maximum dose).
Patient Weight	Approved for pediatric patients weighing at least 35 kg.
Kidney Function	Not recommended for patients with estimated creatinine clearance (CrCl) less than 50 mL/min.
Missed Dose Protocol	If a dose is missed by more than 12 hours from the usual time, the patient is instructed to skip the missed dose and resume the regular schedule.
Rifabutin Co-use	Requires an additional 100 mg Doravirine tablet (Pifeltro) approximately 12 hours after the Delstrigo dose.

The official protocol for Delstrigo is grounded in the stability of the once-daily regimen, which is continued indefinitely for chronic management. The mandatory constraints, such as the minimum weight for pediatric use and the renal function cutoff, define the standardized patient population for this specific fixed-dose tablet.

Research Evidence / Overview of Studies for Delstrigo

---

Evidence from Key Studies for Starting Treatment (Treatment-Naïve)

Delstrigo was studied for use as a starting treatment for adults who had never before taken an HIV medication. The core research involved large Randomized, Controlled Trials (RCTs). These studies research examined the outcomes measured for Delstrigo when it was evaluated against other treatments studied in the research. The primary goal of these studies was the measurement of virologic suppression—tracking the proportion of patients whose HIV-1 viral load was measured below the limit of detection (less than 50 copies/mL) after a defined period.

The research also monitored changes in the body’s immune system, specifically tracking the patterns related to CD4+ T-cell counts. Most of the findings describe patterns observed in the studies over an initial period of 48 weeks. The findings apply only to the populations studied. Data for certain groups, such as those aged 65 and older, remain insufficient.

---

Evidence for Switching Regimens in Virologically Suppressed Patients

Delstrigo was evaluated in studies for patients who were already taking a stable HIV medication regimen and had achieved virologic suppression. The research explored tracking whether viral control was maintained after switching to the single-pill Delstrigo.

The main focus of these trials was studied for tracking the maintenance of viral control. Furthermore, research examined measurements of fasting lipid levels (cholesterol and related fats) following the regimen switch. Findings described the evolution of tracked biomarkers in the observed populations of stably suppressed adults. The existing studies provide limited insight into the outcomes for patients who switch from a regimen while not virologically suppressed.

---

Long-Term Study Durability and Follow-up Periods

The initial core research focused on observation periods of 48 weeks. However, some patient groups were observed in study extensions that reached 96 weeks and even up to 144 weeks or more. These extended studies data show patterns related to the long-term maintenance of viral control and instances of drug resistance development. Long-term effects are not fully established and research is ongoing.

---

What is Still Uncertain About the Delstrigo Research Base

The evidence describes what is known — and what is still uncertain. Long-term effects are not fully established for all outcomes. The follow-up durations were limited in some contexts, such as the initial switch trials, which means evidence regarding the very long-term consequences of switching is still being developed. The evidence research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Common questions about Delstrigo (FAQ)

Q: How is Delstrigo different from other single-pill HIV treatments?

A: Official product information describes Delstrigo as a single-pill regimen that contains Doravirine, a newer-generation NNRTI (non-nucleoside reverse transcriptase inhibitor). Studies were conducted to compare it to other treatments, primarily by tracking viral suppression results and how it affected blood lipid levels. This composition is described as establishing a high barrier against viral resistance.

Q: Are there any long-term health concerns associated with Delstrigo?

A: Regulatory labeling notes that the long-term safety of the medicine continues to be studied. Documented risks that require monitoring include the potential for decreased bone mineral density (BMD) and new onset or worsening renal impairment (kidney problems) with extended use. The need for monitoring of these risks is determined based on individual patient assessment.

Q: Does Delstrigo interact with common over-the-counter pain relievers?

A: Regulatory information notes a caution regarding the concurrent use of high-dose Nonsteroidal Anti-inflammatory Drugs (NSAIDs), as this may increase the concentration of two components of the medicine in the blood. Information about potential interactions for all medicines should be verified using official product labeling.

Q: Is Delstrigo safe for people who have liver conditions?

A: According to official documents, Delstrigo is not recommended for patients who have severe hepatic impairment (a high level of liver disease). Patients with Hepatitis B Virus (HBV) co-infection also need close monitoring of their liver function if they stop taking the medicine.

Q: What is the experience of switching to Delstrigo from a different HIV medicine?

A: Clinical trials have investigated the outcomes for patients switching from a stable HIV regimen to Delstrigo. The research primarily tracks the maintenance of viral control and measurements of fasting lipid levels after the switch.

Q: Does taking Delstrigo affect my ability to drive or operate machinery?

A: Official documents note that side effects such as dizziness or abnormal dreams are possible. These types of adverse reactions could potentially affect a person's ability to drive or safely operate machinery.

Q: Are there any studies comparing Delstrigo use in different age groups?

A: Regulatory documents note that limited clinical data are available for patients aged 65 years and over. Additionally, safety and effectiveness are not established for children under 12 years of age or those weighing less than 35 kg.

Q: Is Delstrigo suitable for someone who has osteoporosis?

A: Regulatory documents describe the potential for decreased bone mineral density (BMD) with long-term use of the medicine. Official information states that patients with pre-existing risk factors for bone disease should undergo close monitoring while on this treatment.

Q: Are there specific dietary restrictions while on Delstrigo?

A: The medicine can officially be taken with or without food. However, regulatory information states that medicines containing sorbitol are not recommended for co-administration, as this can reduce the absorption of one of the drug's components.

Q: Why is Delstrigo only available as a combination pill?

A: Regulatory documents describe the co-formulation as combining two distinct classes of inhibitors (NNRTI and NRTI/NtRTI). This combination is described as establishing a high barrier against viral resistance by targeting the virus with multiple inhibitor classes.

Q: Is the Delstrigo dosage the same for everyone?

A: The standard dose is one fixed-dose tablet daily. However, regulatory documents specify that an additional 100 mg Doravirine tablet is required when co-administered with the medicine Rifabutin. Furthermore, pediatric patients must meet specific age and weight requirements.

Q: What should a woman who is pregnant or planning to conceive know about Delstrigo?

A: Official information states that the medicine's effect on an unborn baby is not known, and a dedicated Antiretroviral Pregnancy Registry exists for monitoring outcomes. Because of the risk of HIV-1 transmission and drug components in milk, breastfeeding is not recommended for women taking Delstrigo.

Q: What is the risk of having a serious allergic reaction to Delstrigo?

A: Official information notes that the medicine is contraindicated (prohibited) in individuals with a known history of hypersensitivity (severe allergy) to lamivudine, one of the components. Immune Reconstitution Inflammatory Syndrome (IRIS) is also a safety pattern associated with combination antiretroviral therapy.

Q: Can Delstrigo be split or crushed to make it easier to swallow?

A: Regulatory documentation specifies that the tablet is a fixed-dose combination that must be swallowed whole. The instruction to swallow the tablet whole is provided to ensure the appropriate delivery of the intended dosage for all three components.

Q: What is the clinical experience with Delstrigo in people with a high viral load?

A: Research findings are presented regarding the proportion of treatment-naïve patients who achieved virologic suppression (which means reducing the viral load to an undetectable level) after a defined period. These findings provide context regarding the measured outcomes when the medicine is used for starting treatment.

Q: Is Delstrigo considered a 'strong' medicine for HIV?

A: Regulatory documents state that the combination is designed to establish a high barrier against the ability of the virus to mutate and develop resistance. This mechanism is officially described as supporting the inhibition of viral replication.

Q: How often do people need blood tests while taking Delstrigo?

A: Regulatory documents note that liver function monitoring is required for several months if treatment is stopped, and renal function must be assessed before and during treatment. The specific frequency of testing is based on clinical assessment.

Q: Will Delstrigo cure HIV?

A: The medicine is officially described as a treatment that helps reduce the amount of HIV in the body and keeps it at a low level. Regulatory documents clearly state that it does not cure HIV.

Q: Are there different brand names for the components of Delstrigo?

A: Regulatory documents confirm the active components are Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate. These components, which combine to form Delstrigo, are also often available in other products under their respective brand names.

Q: How does Delstrigo fit into a typical HIV treatment plan?

A: Official documents indicate Delstrigo is approved for the treatment of HIV-1 infection in adults and adolescents. It is described as a complete regimen used in patients who have never been treated with antiretroviral therapy (treatment-naïve).

Storage Conditions and Environment

Delstrigo tablets must be stored at room temperature, specifically between 20 C to 25 C (68 F to 77 F), with temporary excursions permitted up to 30 C. The medication must be protected from moisture and kept in the original container with the bottle tightly closed; the desiccant packet must not be removed. Storage must strictly avoid refrigeration or freezing. Like all prescription medicines, Delstrigo must be kept out of the reach of children.

Disposal Instructions

Unused, expired, or unneeded tablets must be disposed of as soon as possible by following official regulatory guidelines, such as FDA recommendations for drug take-back programs. The medication must not be flushed down the toilet or poured into a drain to prevent environmental contamination. The official guidelines define the proper non-wastewater disposal procedures.